RegMed Investors’ (RMi) closing bell analysis, the conference week that sets the tone of 2017 or does it?

January 9, 2017 5:43pm

There are a lot of angry investors out there fueled by “some” management’s lack of meeting expectation if they had been set at all.

Bottom line, the issue is share pricing sustainability which will be the KEY WORDS for 2017!

I say today what others won't, so you can do what others can't!

Pre-open indication’s tally:  0 hit and 2 miss but, MY clients ight be early but, made money!

Can you afford to miss the insider view … Click here for access and subscribe:  http://www.regmedinvestors.com/create-account      

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.

U.S. stocks closed mixed on Monday, with and utilities lagging, as investors geared up for the start of earnings season and digested falling oil prices.

The NASDAQ closed UP +10.76 or +0.19% to 5,531.82 and the DOW closed DOWN -76.42 or -0.38% to 19,887.38.

A day in the life of the stem, cell, gene and regenerative therapy (SCGT & RT) sector – the advance/decline line scenario of our 43 covered companies:   

• The open was positive with an A/DL of 25/13 and 5 flats;                      
• The mid-day stayed positive with an A/DL of 23/18 and 2 flats;
• The closing bell continued positive with A/DL of 29/10 and 4 flats;

Henry’omics:

From this morning’s investor’s letter, “JPMorgan conference kicks off in San Francisco. Try getting in and when and if you do, the “pushers” will shove you through the “listening “rooms. 350 companies will be presenting and attendees; what might be revealed, if any substance about the prospects for 2017…”

• As 2016 came to an end, the tumult of the past year shows the truly unpredictable state of “our’ universe!

I am NOT ready to put out a forecast as Q4/16 results have NOT been released! They will be – in my view part the first few preambles of the calculated projections.

• The sector is NOT focused on accountability ... which accounts for much of the uncertainty!

There are a lot of angry investors out there fueled by some management’s lack of meeting expectation if they had been set at all but, bottom line the issue is the continuous decline of share pricing.

• Sustainability will be the KEY WORD for 2017!

For the record, I have been looking and reviewing the conclusions that I made a year ago and they say I did get it right with few wrongs and a high batting average.

Indexes, the ebb and flow:

• The iShares Russell 2000 (IWM) indicated a negative -0.33% in the pre- open and closed DOWN -0.66%.
• The iShares NASDAQ Biotechnology (IBB) did NOT indicate in the pre-open and closed UP +1.43%

Pre-open indication’s tally:  0 hits and 2 miss (CLBS and KITE)

• Caladrius Biosciences (CLBS) closed UP +$0.26 – miss;
• Kite Pharma (KITE) closed UP +$0.75 – miss;

Today’s 5 biggest $ gainers included:

• Spark Therapeutics (ONCE) +$4.00 after Friday’s -$0.19 after Thursday’s -$0.81 after Wednesday’s +$5.81 after Tuesday’s +$3.78;
• AxoGen (AXGN) +$1.00 after Friday’s +$0.50 after Thursday’s -$0.15
• Kite Pharma (KITE) +$0.75 after Friday’s +$1.56 after Thursday’s +$0.72 after Wednesday’s +$3.03 after Tuesday’s +$1.11;
• bluebird bio (BLUE) +$0.60 after Friday’s +$0.70 after Thursday’s -$0.15 after Wednesday’s+$5.80;
• Stemline (STML) +$0.30 after Friday’s +$1.55 after Thursday’s -$0.55 after Wednesday’s +$0.50 after Tuesday’s +0.70;

Today’s 5 biggest $ losers of the session were:

• Neuralstem (CUR) -$0.19;
• BioTime (NYSEMKT: BTX) -$0.09;
• Asterias Biotherapeutics (NYSEMKT: AST) -$0.05;
• Fibrocell (FCSC) -$0.035;
• Pluristem (PSTI) -$0.03;

Flat:                                                                                                      

• International Stem Cell (ISCO) at $1.01;
• ReNeuron (RENE.L) at $2.625;
• Vericel (VCEL) at $2.95;
• Microbot (formerly STEM) at $1.28

The downside trend reflects a pricing trend range of:

• Monday’s decliners ranged from -0.04% <XON> to—4.81% <CUR> in 10 equities;
• Friday’s decliners ranged from -0.12% <MDXG> to-4.82% <CLLS> in 23 equities;
• Thursday’s decliners ranged from -0.22% <BLUE> to -8.96% <ADVM> in 25 equities;
• Wednesday’s decliners ranged from -0.19% <MESO> to -4.09% <VTGN> in 6 equities;
• Tuesday’s decliners ranged from +0.24% <BLUE> to +11.67% <CUR>   in 30 equities;
• Last Monday was a holiday;

The upside shows a pricing trend range of:

• Monday’s ranged from +0.21% <BLCM> to +15.71% <NWBO> in 29 equities;
• Friday’s gainers ranged from +0.40% <BCLI> to +13.66% <STML> in 18 equities;
• Thursday’s gainers ranged from +0.17% <QURE> to +21.99% <FCSC> in 15 equities;
• Wednesday’s gainers ranged from +0.56% <AXGN> to +13.56 <ADVM> in 34 equities;
• Tuesday’s gainers ranged from -0.27% <RGNX> to -5.37% <IMUC> in 12 equities;
• Last Monday was a holiday;

The week’s initiation:

• Monday’s 29 gainers followed Friday’s 18, Thursday’s 15, Wednesday’s 34, Tuesday’s 30 and last was a Monday’s holiday
• Monday’s 10 decliners followed Friday’s 23, Thursday’s 25, Wednesday’s 6, Tuesday’s 12 and last Monday’s holiday

Review my fear gauge or the CBOE Volatility Index (VIX):

·         Monday traded near 11.6;

·         Friday traded near 11.3;

·         Thursday traded near 11.7;

·         Wednesday traded near 11.9;

·         Tuesday traded near 12.9;

·         Last Monday was a holiday;

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.